Skip to main content

Table 1 Patient and tumor characteristics stratified by ER Status of recurrent tumor

From: TROP2 methylation and expression in tamoxifen-resistant breast cancer

 

ERpos primary to ERneg (n = 6)

ERpos primary to ERpos (n = 12)

  

Patients

  

 Age (in years) mean (SD), range

  

  At primary

53 (8.1), 42–65

58 (15.8), 37–84

  

  At recurrence

60 (6.1), 53–68

65 (15.6), 40–90

  

 Menopausal n (%)

  

  At primary

2 (33%)

6 (50%)

  

  At recurrence

3 (50%)

8 (66.6%)

  

TTR (in months) mean (SD), range

82.8 (77.6) 17–216

84.1 (72.5), 12–252

  
 

ERpos primary (n = 6)

ERneg recurrent (n = 6)

ERpos primary (n = 12)

ERpos recurrent (n = 12)

Tumors

 PR status n (%)

  +

3 (50)

0

11 (91.6)

9 (75)

  −

3 (50)

6 (100)

1 (8.3)

3 (25)

 HER2 status n (%)

  +

2 (33.3)

3 (50)

1 (8.3)

2 (16.6)

  −

4 (66.6)

3 (50)

11 (91.6)

10 (83.4)

 Ki67 IHC n (%)

  Low (≤ 15)

6 (100)

4 (66.6)

9 (75)

8 (66.6)

  High (> 15)

0

2 (33.3)

3 (25)

4 (33.4)

 Tumor grade n (%)a

  0

2 (33.3)

2 (33.3)

1 (9.1)

2 (16.7)

  1

0

0

3 (27.3)

2 (16.7)

  2

3 (50)

0

4 (36.3)

3 (25)

  3

1 (16.6)

4 (66.6)

3 (27.3)

5 (41.6)

 Tumor type n (%)

  DCIS

2 (33.3)

2 (33.3)

1 (8.3)

2 (16.7)

  IDC

3 (50)

4 (66.6)

8 (66.7)

6 (50)

  ILC

0

0

2 (16.7)

3 (25)

  IDLC

1 (16.6)

0

1 (8.3)

1 (8.3)

  1. See text for scoring of ER, PR, HER2 and Ki67
  2. TTR time to recurrence
  3. aIndicates that data are missing for some samples; percentages are calculated on the available data